Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 135 of 1,261
  1. US 11912997

    RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  2. US 11912778

    Methods of engineering transferrin receptor binding polypeptides

    DENALI THERAPEUTICS INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  3. US 11912780

    Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

    Actinium Phamaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  4. US 11912762

    Method of treating osteoarthritis by administering an anti-connexin 43 antibody

    The Board of Regents of the University of Texas System · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  5. US 11912682

    Isoindolinone compounds

    Monte Rosa Therapeutics AG · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  6. US 11912714

    Spiropyrrolidine derived antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  7. US 11912695

    Benzodiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  8. US 11910788

    Mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  9. US 11911368

    Method of treatment of CNS disorders

    Supernus Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  10. US 11911359

    Stimulation of an immune response by cationic lipids

    PDS Biotechnology Corporation · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  11. US 11911446

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  12. US 11913012

    Cardiac cell reprogramming with myocardin and ASCL1

    Tenaya Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  13. US 11912750

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  14. US 11911434

    Stable antibody-drug conjugate, preparation method therefor, and use thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  15. US 11912758

    Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

    The Board of Regents of the University of Texas System · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  16. US 11911515

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  17. US 11911484

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  18. WO 2024039256

    RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON

    BIAL PORTELA & CA SA [PT] · Granted Feb 22, 2024 · Expires Feb 17, 2044

    granted
  19. US 11903994

    Dosing regimens

    Apellis Pharmaceuticals, Inc. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  20. US 11904006

    Poly(diaminosulfide) particle-based vaccine

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  21. US 11903930

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  22. US 11903973

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  23. US 11903920

    Cannabinoid formulation: production method and use

    CHIROSYN DISCOVERY TECHNOLOGIES INC. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  24. US 11903966

    Intracellular genomic transplant and methods of therapy

    Regents of the University of Minnesota · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.